Show simple item record

dc.contributor.authorCorrie, P. G.
dc.contributor.authorQian, W.
dc.contributor.authorBasu, B.
dc.contributor.authorValle, Juan W
dc.contributor.authorFalk, S.
dc.contributor.authorLwuji, C.
dc.contributor.authorWasan, H.
dc.contributor.authorPalmer, D.
dc.contributor.authorScott-Brown, M.
dc.contributor.authorWadsley, J.
dc.contributor.authorArif, S.
dc.contributor.authorBridgewater, J.
dc.contributor.authorPropper, D.
dc.contributor.authorGillmore, R.
dc.contributor.authorGopinathan, A.
dc.contributor.authorSkells, R.
dc.contributor.authorBundi, P.
dc.contributor.authorBrais, R.
dc.contributor.authorDalchau, K.
dc.contributor.authorBax, L.
dc.contributor.authorChhabra, A.
dc.contributor.authorMachin, A.
dc.contributor.authorDayim, A.
dc.contributor.authorMcAdam, K.
dc.contributor.authorCummins, S.
dc.contributor.authorWall, L.
dc.contributor.authorEllis, R.
dc.contributor.authorAnthoney, A.
dc.contributor.authorEvans, J.
dc.contributor.authorMa, Y. T.
dc.contributor.authorIsherwood, C.
dc.contributor.authorNeesse, A.
dc.contributor.authorTuveson, D.
dc.contributor.authorJodrell, D. I.
dc.date.accessioned2020-06-16T11:03:10Z
dc.date.available2020-06-16T11:03:10Z
dc.date.issued2020en
dc.identifier.citationP. G. Corrie, W. Qian, B. Basu, J. W. Valle et al. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer. 2020.en
dc.identifier.pmid32350413en
dc.identifier.doi10.1038/s41416-020-0846-2en
dc.identifier.urihttp://hdl.handle.net/10541/623011
dc.description.abstractBACKGROUND: Nab-paclitaxel plus gemcitabine (nabP+gemcitabine) offers modest survival gains for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Sequential scheduling of nabP+gemcitabine in a PDAC mouse model improved efficacy; this hypothesis was tested in a clinical trial. METHODS: Patients with previously untreated metastatic PDAC were randomised to receive nabP+gemcitabine administered either concomitantly on the same day, or sequentially, with gemcitabine administered 24 h after nabP. The primary outcome measure was progression-free survival (PFS). Secondary outcome measures were objective response rate (ORR), overall survival (OS), safety, quality of life (QoL) and predictive biomarkers. RESULTS: In total, 71 patients received sequential (SEQ) and 75 concomitant (CON) treatment. Six-month PFS was 46% with SEQ and 32% with CON scheduling. Median PFS (5.6 versus 4.0 months, hazard ratio [HR] 0.67, 95% confidence interval [95% CI] 0.47-0.95, p = 0.022) and ORR (52% versus 31%, p = 0.023) favoured the SEQ arm; median OS was 10.2 versus 8.2 months (HR 0.93, 95% CI 0.65-1.33, p = 0.70). CTCAE Grade /=3 neutropaenia incidence doubled with SEQ therapy but was not detrimental to QoL. Strongly positive tumour epithelial cytidine deaminase (CDA) expression favoured benefit from SEQ therapy (PFS HR 0.31en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-020-0846-2en
dc.titleScheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaen
dc.typeArticleen
dc.contributor.departmentCambridge University Hospitals NHS Foundation Trust (Addenbrooke's Hospital), Cambridge, UK.en
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]
refterms.dateFOA2020-06-16T12:16:10Z


Files in this item

Thumbnail
Name:
32350413.pdf
Size:
974.9Kb
Format:
PDF
Description:
FROM CORE

This item appears in the following Collection(s)

Show simple item record